Loading stock data…
$16.69+0.18 (+1.09%)
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases.
Sarepta Therapeutics, Inc. in the Healthcare sector is trading at $16.69 with a market capitalization of $2.2B. Wall Street consensus targets $21.64 (22 analysts), implying a +29.6% move over the next 12 months. The stock is currently 32% below its 52-week high of $24.68, remaining 11.9% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $401.25M↓ | $730.80M↑ | $442.93M↑ | $399.36M↓ | $611.09M |
| Gross Profit | $251.87M↓ | $622.03M↑ | $44.23M↓ | $248.58M↓ | $458.53M |
| Operating Income | $52.29M↓ | $358.43M↑ | -$410.08M↓ | -$62.88M↓ | $115.58M |
| Net Income | -$4.89M↓ | $330.96M↑ | -$282.85M↓ | -$179.95M↓ | $196.89M |
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases...